GlassScriptPhysician profile
Bradley Scharf
NPI 1427060169
$3,646.60
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $46.35 · 2021: $330 · 2022: $214 · 2023: $2,489 · 2024: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $2,315 · Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $2,315.43 |
| Food and Beverage | $445.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $2,315.43 | 2023 | |
| Aerie Pharmaceuticals, INC. | $324.22 | 2019-2021 | |
| Alcon Vision LLC | $289.53 | 2019-2022 | |
| Abbvie INC. | $159.07 | 2022-2024 | Alphagan P, Lumigan, Vuity |
| Rxsight INC | $150.00 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $67.65 | 2019-2022 | |
| Oyster Point Pharma, INC. | $66.52 | 2023 | Tyrvaya |
| Coopervision INC. | $56.50 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $43.89 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $41.01 | 2019 | |
| Horizon Therapeutics Plc | $34.16 | 2021-2023 | Tepezza |
| Astellas Pharma US INC | $28.30 | 2024 | Izervay |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $17.88 | 2024 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.39 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $15.65 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Scharf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.